2Asist. Dr.. Okmeydanı Eğitim ve Araştırma Hastanesi, Göz Kliniği, İstanbul, Türkiye
3Prof. Dr.. Okmeydanı Eğitim ve Araştırma Hastanesi, Göz Kliniği, İstanbul, Türkiye Purpose: To evaluate the efficacy of early switch to intravitreal dexamethasone implantation (IDI) in afl ibercept resistant diabetic macular edema (DME)
Materials and methods: In this retrospective study 21 eyes of 21 patients with persistent diabetic macular edema, who underwent a single dose IDI were examined. All of the patients had a history of at least fi ve intravitreal afl ibercept (IVA) injections. Main outcome measures were changes in best-corrected visual acuity (BCVA), central macular thickness (CMT) at 1, 2, 3 months after IDI treatment.
Results: Mean follow-up time and average number of previous IVA injections was 19.24±1.67 months and 5.35±0.6. The mean BCVA was
improved from 0.73±0.57logMAR to 0.49±0.34logMAR (p=0.011), 0.34±0.29 logMAR(p=0.001), and 0.36±0.27 logMAR(p=0.001) at 1,2
and 3 months, respectively. The mean CMT was decreased from 434±90 ?m to 335±74 ?m (p<0.001), 328±46 ?m (p<0.001) and 350±85 ?m
(p=0.009) at 1,2 and 3 months.
